Patents by Inventor Max RODNICK-SMITH

Max RODNICK-SMITH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230416697
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.
    Type: Application
    Filed: March 2, 2023
    Publication date: December 28, 2023
    Applicants: Antidote Therapeutics, Inc., Board of Regents, The University of Texas System
    Inventors: Matthew W. KALNIK, Thomas THISTED, Everett STONE, Charles C. REED, Max RODNICK-SMITH
  • Patent number: 11597916
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 7, 2023
    Assignees: ANTIDOTE THERAPEUTICS, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Matthew W. Kalnik, Thomas Thisted, Everett Stone, Charles C. Reed, Max Rodnick-Smith
  • Publication number: 20200224176
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.
    Type: Application
    Filed: February 2, 2018
    Publication date: July 16, 2020
    Applicants: ANTIDOTE THERAPEUTICS, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Matthew W. KALNIK, Thomas THISTED, Everett STONE, Charles C. REED, Max RODNICK-SMITH